search
Back to results

Events Preceding Interstitial Cystitis (EPIC) (EPIC)

Primary Purpose

Cystitis, Interstitial

Status
Completed
Phase
Locations
United States
Study Type
Observational
Intervention
Sponsored by
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an observational trial for Cystitis, Interstitial focused on measuring Cystitis, Interstitial, Case-Control Studies, Risk Factors

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria: Female Adults(18 and over) who have had symotoms of IC for 12 months or fewer - Exclusion Criteria: Males,children, those who do not have symptoms of IC or those who have had symtoms for greater than 12 months. -

Sites / Locations

  • University of Maryland School of Medicine

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

First Posted
November 3, 2005
Last Updated
March 2, 2010
Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
search

1. Study Identification

Unique Protocol Identification Number
NCT00248664
Brief Title
Events Preceding Interstitial Cystitis (EPIC)
Acronym
EPIC
Official Title
A Case Control Study of Interstitial Cystitis
Study Type
Observational

2. Study Status

Record Verification Date
March 2010
Overall Recruitment Status
Completed
Study Start Date
March 2004 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
November 2008 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

4. Oversight

5. Study Description

Brief Summary
EPIC is a case/control study that seeks to identify the risk factors for interstitial cystitis by comparing the experiences and medical histories of 400 women who recently developed IC with 400 similar people who do not have the disease.
Detailed Description
This project is a systematic, national study of incident IC cases and controls matched by age and gender. By telephone interview and medical record review, we compare exposures of cases and controls seeking significant differences which may be risk factors for IC. This cohort of incident IC cases will initiate a natural history study of the disease. Specific Aim 1. To test the hypothesis that certain features that precede onset of IC symptoms, e.g., bacterial cystitis, distinguish IC cases from controls matched for age and gender, and may be risk factors for the disease. Specific Aim 2. To test the hypotheses that patients with IC have higher prevalences of certain non bladder syndromes, e.g., irritable bowel syndrome, than do controls matched for age and gender. Specific Aim 3. To test the hypothesis that urine APF, HB EGF, and/or EGF are sensitive and specific diagnostic markers for IC in patients with symptoms of ÿ12 months. Specific Aim 4. To test the hypotheses that, in an incident cohort, patients with IC have remissions and that certain clinical features, e.g., bacterial cystitis at disease onset, are prognostic factors for remissions.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cystitis, Interstitial
Keywords
Cystitis, Interstitial, Case-Control Studies, Risk Factors

7. Study Design

Enrollment
400 (Anticipated)

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Female Adults(18 and over) who have had symotoms of IC for 12 months or fewer - Exclusion Criteria: Males,children, those who do not have symptoms of IC or those who have had symtoms for greater than 12 months. -
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
John W Warren, MD
Organizational Affiliation
University of Maryland, Baltimore
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Maryland School of Medicine
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21201
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Events Preceding Interstitial Cystitis (EPIC)

We'll reach out to this number within 24 hrs